In questo episodio vengono illustrate le diverse tossicità neurologiche degli agenti ormonali di nuova generazione (ARPI) nel trattamento del tumore prostatico, evidenziando effetti come deterioramento cognitivo, crisi epilettiche e disturbi psichiatrici.
Bibliografia
- Nowakowska MK, et al. Association of Second-generation Antiandrogens With Depression Among Patients With Prostate Cancer. JAMA Netw Open. 2021 Dec 1;4(12):e2140803.
- Tsao PA, et al. Mental health care utilization among men with castration-resistant prostate cancer receiving abiraterone or enzalutamide. Cancer Med. 2023 Aug;12(15):16490-16501.
- Thiery-Vuillemin A, et al. Impact of Abiraterone Acetate plus Prednisone or Enzalutamide on Patient-reported Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer: Final 12-mo Analysis from the Observational AQUARiUS Study. Eur Urol. 2020 Mar;77(3):380-387.
- Dharmani C, et al. Risk Factors for and Incidence of Seizures in Metastatic Castration-Resistant Prostate Cancer: A Real-World Retrospective Cohort Study. Clin Drug Investig. 2017 Dec;37(12):1183-1190.
- Slovin S, et al. Seizure Rates in Enzalutamide-Treated Men With Metastatic Castration-Resistant Prostate Cancer and Risk of Seizure: The UPWARD Study. JAMA Oncol. 2018 May 1;4(5):702-706.
